TY - JOUR
T1 - Heterogeneity in ALSFRS-R decline and survival
T2 - a population-based study in Italy
AU - Mandrioli, Jessica
AU - Biguzzi, Sara
AU - Guidi, Carlo
AU - Sette, Elisabetta
AU - Terlizzi, Emilio
AU - Ravasio, Alessandro
AU - Casmiro, Mario
AU - Salvi, Fabrizio
AU - Liguori, Rocco
AU - Rizzi, Romana
AU - Pietrini, Vladimiro
AU - Borghi, Annamaria
AU - Rinaldi, Rita
AU - Fini, Nicola
AU - Chierici, Elisabetta
AU - Santangelo, Mario
AU - Granieri, Enrico
AU - Mussuto, Vittoria
AU - De Pasqua, Silvia
AU - Georgoulopoulou, Eleni
AU - Fasano, Antonio
AU - Ferro, Salvatore
AU - D'Alessandro, Roberto
AU - ERRALS Group
PY - 2015/12/1
Y1 - 2015/12/1
N2 - Very few studies examined trend over time of the revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) and factors influencing it; previous studies, then, included only patients attending tertiary ALS Centres. We studied ALSFRS-R decline, factors influencing this trend and survival in a population-based setting. From 2009 onwards, a prospective registry records all incident ALS cases among residents in Emilia Romagna (population: 4.4 million). For each patient, demographic and clinical details (including ALSFRS-R) are collected by caring physicians at each follow-up. Analysis was performed on 402 incident cases (1279 ALSFRS-R assessments). The average decline of the ALSFRS-R was 0.60 points/month during the first year after diagnosis and 0.34 points/month in the second year. ALSFRS-R decline was heterogeneous among subgroups. Repeated measures mixed model showed that ALSFRS-R score decline was influenced by age at onset (p < 0.01), phenotype (p = 0.01), body mass index (BMI) (p < 0.01), progression rate at diagnosis (ΔFS) (p < 0.01), El Escorial Criteria-Revised (p < 0.01), and FVC% at diagnosis (p < 0.01). Among these factors, at multivariate analysis, only age, site of onset and ΔFS independently influenced survival. In this first population-based study on ALSFRS-R trend, we confirm that ALSFRS-R decline is not homogeneous among ALS patients and during the disease. Factors influencing ALSFRS-R decline may not match with those affecting survival. These disease modifiers should be taken into consideration for trials design and in clinical practice during discussions with patients on prognosis.
AB - Very few studies examined trend over time of the revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) and factors influencing it; previous studies, then, included only patients attending tertiary ALS Centres. We studied ALSFRS-R decline, factors influencing this trend and survival in a population-based setting. From 2009 onwards, a prospective registry records all incident ALS cases among residents in Emilia Romagna (population: 4.4 million). For each patient, demographic and clinical details (including ALSFRS-R) are collected by caring physicians at each follow-up. Analysis was performed on 402 incident cases (1279 ALSFRS-R assessments). The average decline of the ALSFRS-R was 0.60 points/month during the first year after diagnosis and 0.34 points/month in the second year. ALSFRS-R decline was heterogeneous among subgroups. Repeated measures mixed model showed that ALSFRS-R score decline was influenced by age at onset (p < 0.01), phenotype (p = 0.01), body mass index (BMI) (p < 0.01), progression rate at diagnosis (ΔFS) (p < 0.01), El Escorial Criteria-Revised (p < 0.01), and FVC% at diagnosis (p < 0.01). Among these factors, at multivariate analysis, only age, site of onset and ΔFS independently influenced survival. In this first population-based study on ALSFRS-R trend, we confirm that ALSFRS-R decline is not homogeneous among ALS patients and during the disease. Factors influencing ALSFRS-R decline may not match with those affecting survival. These disease modifiers should be taken into consideration for trials design and in clinical practice during discussions with patients on prognosis.
KW - ALSFRS-R
KW - Amyotrophic lateral sclerosis
KW - Disease progression
KW - Heterogeneity
KW - Population-based study
UR - http://www.scopus.com/inward/record.url?scp=84989179389&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84989179389&partnerID=8YFLogxK
U2 - 10.1007/s10072-015-2343-6
DO - 10.1007/s10072-015-2343-6
M3 - Article
C2 - 26205535
SN - 1590-1874
VL - 36
SP - 2243
EP - 2252
JO - Neurological Sciences
JF - Neurological Sciences
IS - 12
ER -